Barclays PLC Century Therapeutics, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 70,475 shares of IPSC stock, worth $54,265. This represents 0.0% of its overall portfolio holdings.

Number of Shares

70,475

Previous 61,945 13.77%

Holding current value

$54,265

Previous $106,000 33.02%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$1.0 - $1.72 $8,530 - $14,671	8,530 Added 13.77%	70,475 $71,000
Q3 2024 Nov 15, 2024	BUY	$1.44 - $3.29 $65,947 - $150,672	45,797 Added 283.61%	61,945 $106,000
Q2 2024 Aug 14, 2024	SELL	$2.46 - $4.05 $774 - $1,275	-315 Reduced 1.91%	16,148 $42,000
Q1 2024 May 15, 2024	SELL	$3.19 - $5.32 $50,149 - $83,635	-15,721 Reduced 48.85%	16,463 $69,000
Q4 2023 Feb 15, 2024	BUY	$1.28 - $3.32 $35,884 - $93,076	28,035 Added 675.7%	32,184 $107,000
Q3 2023 Nov 07, 2023	SELL	$2.0 - $3.23 $1,040 - $1,679	-520 Reduced 11.14%	4,149 $8,000
Q2 2023 Aug 03, 2023	SELL	$2.91 - $3.53 $16,342 - $19,824	-5,616 Reduced 54.6%	4,669 $15,000
Q1 2023 May 04, 2023	BUY	$3.4 - $5.11 $16,581 - $24,921	4,877 Added 90.18%	10,285 $35,000
Q4 2022 Feb 13, 2023	BUY	$4.84 - $11.58 $22,041 - $52,735	4,554 Added 533.26%	5,408 $28,000
Q3 2022 Nov 03, 2022	SELL	$8.57 - $13.1 $1,336 - $2,043	-156 Reduced 15.45%	854 $8,000
Q2 2022 Aug 12, 2022	SELL	$7.96 - $12.43 $14,367 - $22,436	-1,805 Reduced 64.12%	1,010 $8,000
Q1 2022 May 16, 2022	BUY	$11.62 - $15.92 $32,710 - $44,814	2,815 New	2,815 $36,000

Others Institutions Holding IPSC

# of Institutions

Shares Held

33.6M

Call Options Held

9.7K

Put Options Held

1.5K

View Full List

About Century Therapeutics, Inc.

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $45.3M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

More about IPSC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account